Lymphoma
is a cancer caused in lymphocytes of the body, i.e. white blood
cells. It is of two types – Hodgkin’s Lymphoma and Non-Hodgkin’s
Lymphoma. Hodgkin’s Lymphoma can be characterized into two
categories – classic and nodular lymphocyte predominant. Some of
the signs indicating presence of Hodgkin’s Lymphoma in the body is
fever, sudden weight loss, and swollen lymph nodes. Hodgkin’s
Lymphoma is mostly treated with chemotherapy alone or with the
combination of radiotherapy.
Request
Sample of This Report:
https://www.coherentmarketinsights.com/insight/request-sample/2658
Global
Hodgkin’s Lymphoma Treatment Market Drivers
Approvals
of the drugs by regulatory bodies for the treatment of Hodgkin’s
lymphoma is expected to drive the global Hodgkin’s lymphoma market
growth. In 2018, Seattle Genetics, Inc. received the Health Canada
approval for its supplemental New Drug Submission that expands the
use of Adcetris (brentuximab vedotin) in combination with AVD
(Adriamycin, vinblastine and dacarbazine) chemotherapy in patients
with previously untreated Stage IV Hodgkin lymphoma (HL). Adcetris is
indicated for the treatment of adult patients with previously
untreated Stage III or IV classical Hodgkin lymphoma (cHL), in
combination with doxorubicin, vinblastine, and dacarbazine.
Furthermore,
key players are constantly trying to expand the indications of their
already approved drug. For instance, in March 2017, Merck & Co.
Inc. received an approval by U.S. Food & Drug Administration
(FDA) of the drug, Keytruda for the treatment of classical Hodgkin’s
lymphoma. It is approved on the basis of response durability and
tumor response rate and is supposed to be administered intravenously
into patients. It was originally approved in 2014. Such frequent
approvals of drugs by regulatory bodies are expected to impact
positively on the global Hodgkin’s lymphoma treatment market
growth.
Global
Hodgkin’s Lymphoma Treatment Market Regional Analysis
North
America is expected to hold a dominant position in the global
Hodgkin’s lymphoma market over the forecast period. Frequent
research and development activities done by the government and other
organizations is expected to drive the North America Hodgkin’s
lymphoma treatment market growth. For instance, in December 2016,
Ohio State University Comprehensive Cancer Center and National Cancer
Institute (NCI) commenced a U.S. FDA clinical trial of Ibrutinib in
combination with Nivolumab, in the patients suffering from classical
Hodgkin’s Lymphoma, in the U.S to study its efficacy. Ibritunib may
block the cancer cell growth by blocking the enzymes responsible for
growth and Nivolumab may block cancer cells by targeting different
cells. Currently, it’s in the second phase of clinical trials. The
study involves 17 participants and is estimated to be completed by
2020.
Global
Hodgkin’s Lymphoma Treatment Market Key Players
Some
of the major players operating in the global Hodgkin’s lymphoma
treatment market include Emcure Pharmaceuticals Pvt. Ltd., Aspen
Global Inc., Pfizer Inc., Ono Pharmaceuticals Co. Ltd., Corden Pharma
Latina SPA, Horizon Pharma USA Inc., Cipla Ltd., Lediant Biosciences
Inc., Jansenn Research and Development LLC, and Merck & Co., Inc.
Global
Hodgkin’s Lymphoma Treatment Market Taxonomy
The
global Hodgkin’s lymphoma treatment market is segmented on the
basis of treatment type, route of administration, distribution
channel, and regions.
By
Treatment Type:
Immunotherapy
Monoclonal
Antibody
•
Conjugated
-
Brentuximab Vedotin
•
Non-conjugated
-
Nivolumab
-
Pembrolizumab
-
Brentuximab
•
Chemotherapy
•
Others
By
Route of Administration:
-
Oral
-
Injectable
Browse
In-Depth Analysis Research Report:
https://www.coherentmarketinsights.com/ongoing-insight/hodgkins-lymphoma-treatment-market-2658
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm
offering action-ready syndicated research reports, custom market
analysis, consulting services, and competitive analysis through
various recommendations related to emerging market trends,
technologies, and potential absolute dollar opportunity.
Contact
Us:
Mr.
Shah
Coherent
Market Insights
1001
4th Ave,
#3200
Seattle,
WA 98154
Tel:
+1-206-701-6702
No comments:
Post a Comment